Premium
UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY
Author(s) -
Wu J. Q.,
Seymour J. F.,
Eichhorst B.,
Hillmen P.,
Kipps T.,
Langerak A. W.,
Owen C.,
Dubois J.,
Mellink C.,
van der KevieKersemaekers A.,
Chyla B.,
Jiang Y.,
Boyer M.,
ThadaniMulero M.,
Lefebure M.,
Kater A. P.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.50_2880
Subject(s) - medicine , bendamustine , venetoclax , rituximab , chronic lymphocytic leukemia , oncology , gastroenterology , minimal residual disease , clone (java method) , refractory (planetary science) , progression free survival , leukemia , lymphoma , chemotherapy , genetics , biology , dna , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom